Genomic Health, Inc. (NASDAQ:GHDX) insider Kim Mceachron sold 5,335 shares of Genomic Health stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $60.01, for a total value of $320,153.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Genomic Health stock opened at $56.20 on Friday. The company’s 50-day moving average price is $54.75. The company has a market cap of $2.14 billion, a P/E ratio of 53.52 and a beta of 1.07. Genomic Health, Inc. has a 52-week low of $50.77 and a 52-week high of $92.18. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, May 7th. The medical research company reported $0.34 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.05. The business had revenue of $108.80 million during the quarter, compared to the consensus estimate of $106.75 million. Genomic Health had a return on equity of 18.70% and a net margin of 10.35%. The business’s quarterly revenue was up 17.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) EPS. On average, equities research analysts forecast that Genomic Health, Inc. will post 1.46 EPS for the current fiscal year.

GHDX has been the subject of several research analyst reports. BidaskClub upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 4th. Zacks Investment Research downgraded Guaranty Federal Bancshares from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. ValuEngine downgraded Valero Energy from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Deutsche Bank set a $18.00 price objective on Commercial Metals and gave the stock a “buy” rating in a report on Thursday, May 30th. Finally, Canaccord Genuity lifted their price objective on ServiceNow from $285.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, May 8th. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $64.86.

Several institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. grew its stake in shares of Genomic Health by 0.5% during the 4th quarter. Macquarie Group Ltd. now owns 38,200 shares of the medical research company’s stock valued at $2,461,000 after purchasing an additional 200 shares during the period. Royce & Associates LP grew its stake in shares of Genomic Health by 22.8% during the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 273 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in shares of Genomic Health by 166.0% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 493 shares during the period. Advisor Group Inc. grew its stake in shares of Genomic Health by 34.9% during the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 516 shares during the period. Finally, Quantamental Technologies LLC grew its stake in shares of Genomic Health by 19.1% during the 1st quarter. Quantamental Technologies LLC now owns 3,332 shares of the medical research company’s stock valued at $233,000 after acquiring an additional 534 shares during the period. Institutional investors and hedge funds own 95.54% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Further Reading: Is it Safe to Invest in Commodities?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.